Objective: Our purpose was to evaluate coronary artery disease (CAD) prevalence and prognosis according to cardiometabolic (CM) risk.
Standard risk assessment guidelines regard type 2 diabetes mellitus (T2DM) as a coronary heart disease risk equivalent(1; 2). Although a subgroup of patients with T2DM may have minimal coronary artery disease (CAD) (3) , coronary heart disease is the most common cause of death in patients with T2DM. Moreover, the presence of T2DM is associated with a poorer prognosis after a myocardial infarction (MI) (4) As a result, the American Diabetes Association recommends primary prevention measures for CAD in all patients with T2DM, and particularly intensive secondary prevention among those with T2DM and CAD (5) .
However, there is insufficient data to suggest that patients without T2DM who have cardiometabolic (CM) risk factors, such as obesity, dysglycemia, atherogenic dyslipidemia or hypertension, should be treated as aggressively as patients with T2DM. While such patients have been termed to be at increased CM risk (6) (7) (8) , not all of them will have the same extent of anatomical CAD and risk of cardiovascular disease(5; 9). Therefore, improved methods for CAD detection and risk assessment could be useful in improving patient outcome.
Nuclear myocardial perfusion imaging has been shown to be useful in risk stratification among individuals with T2DM (10) , although in the contemporary era of widespread medical therapy, such testing did not lead to improvement in cardiovascular outcomes among asymptomatic patients with T2DM. (11) Furthermore, in comparison to patients without T2DM, a shorter "warranty period" (i.e. favorable prognosis with normal results) has been found (12; 13) possibly reflecting the fact that patients with T2DM are more likely to have diffuse coronary atherosclerosis and accelerated disease progression. More recently, the use of cardiac computed tomography angiography (CCTA) has been evaluated among patients with T2DM and showed greater burden of disease in comparison to patients without T2DM as well as worse prognosis. (14; 15) However, these studies have been limited to all-cause mortality and did not 
Cardiometabolic Risk factors
Review of all clinical data prior to the CCTA was used to verify the presence or absence of risk (27) , both of which include BMI as a means of defining CM risk.
Cardiovascular Outcomes
All patient charts were reviewed by two cardiologists who were blinded to CCTA results for adjudication of cardiovascular events. In order to ensure that events outside of our healthcare network are captured, a standardized questionnaire was mailed to each patient in a manner similar to prior studies. (28; 29) In addition, patients had the option of completing a web-based version of the questionnaire via the REDCap (Research Electronic Data Capture) system, (30) which is encrypted, secure, and HIPAA compliant. For patients who did not reply to the questionnaire upon repeated mailings, scripted phone interviews were performed based on the questionnaire. In order to avoid erroneous diagnoses from self-reported events, all self-reported events were verified via outside medical record review by two cardiologists, blinded to CTA results with discordant events adjudicated by consensus. Using all available data, the causes of deaths were adjudicated by two cardiologists blinded to the CTA results with cardiovascular mortality defined as a primary cause of acute MI, atherosclerotic coronary vascular disease, congestive heart failure, valvular heart disease, arrhythmic heart disease, stroke, or other structural or primary cardiac cause of death.
Statistical analysis
Continuous variables are reported as mean +/-standard deviation. Categorical variables are reported as counts and proportions. Continuous variables were compared between groups using analysis of variance techniques. Median segment scores were compared between groups using the Kruskal-Wallis test. Categorical variables were compared using chi-squared test or
Fisher's exact test, where appropriate. Univariable and stepwise multivariable logistic regression was used to assess the association between covariates and the presence of obstructive CAD (defined as above). For purposes of multivariable logistic regression for variables associated with obstructive CAD only, missing HbA1c (HbA1c was available in 78% of patients with T2DM) was imputed based on linear regression of HbA1c with available fasting glucose levels for patients without HbA1c as has been previously validated.(36; 37) The Kaplan Meier method was used to assess event-free survival for the various outcomes of interest (as defined above). To account for baseline differences in patient characteristics for patients with T2DM
who are treated or not treated with exogenous insulin, a propensity weighted analysis was conducted. In order to adjust for these baseline differences, we used a two-step process (38; 39) of first evaluating a priori all variables associated with insulin therapy in a logistic model and including those baseline characteristics with a p-value below 0.10 in a final propensity score, which represented a summary statistic for prediction of treatment with insulin therapy. Secondly, we included the propensity score in a propensity weighted Cox-proportional hazards model for prediction of MACE. Such an approach controls for confounding due to baseline differences in each cohort in addition to the effect of non-randomized treatment allocation to statin therapy.
Univariable and multivariable propensity weighted Cox proportional hazards models were constructed to compare risk between strata. Predictors with a p <0.10 in univariable analysis were included in the propensity weighted multivariable model. All statistics were performed using Stata version 12.1 (Statacorp, College Station, TX).
Results

Patient population
1,148 patients met inclusion criteria, of which 10 patients (0.9%) had no available outcomes follow-up and 20 patients (1.7%) had un-interpretable CTA, leaving 1,118 patients available for analysis ( Table 1) . The most common indication for referral was chest pain symptoms in 641(57%) followed by abnormal stress testing in 278(25%) and pre-operative assessments in 66(6%) of patients.
There were 483 (43%) patients without T2DM with <3 CM risk factors, and 187 (17%) patients without T2DM and ≥3 CM risk factors. Among the remaining 451 (40%) patients with T2DM, 367 did not require insulin and 84 were were insulin requiring.
Over a mean follow-up of 3.1 years, there were 46 (4.1%) all-cause deaths, 21 (1.9%) cardiovascular deaths, 13(1.2%) MI, 13(1.2%) unstable angina without revascularization, and 34 (3.1%) late coronary revascularizations.
Baseline Characteristics
As expected, significant differences in prevalence of baseline risk factors occurred across CM risk groups (Table 1) . Hemoglobin A1c was progressively higher across groups of increased CM risk (p<0.001).
Prevalence, Severity, and Extent of CAD Across Cardiometabolic Risk
Across a spectrum of increasing CM risk, there was increasing prevalence of any CAD from 51% among those with no T2DM and <3 CM risks, to 60% among those with no T2DM
and ≥3 CM risks, to 71% among those with T2DM not requiring insulin, to 80% among those with T2DM requiring insulin (p<0.001). Although statistically significant differences occurred (p<0.001), the prevalence of non-obstructive CAD was numerically similar across all patient groups, ranging from 36% to 42% to 41% to 33%. Finally, obstructive CAD was markedly increased according to CM risk, ranging from 15 to 46% (p<0.001). When considering extent of disease, SIS and SSS both increased significantly across groups of increasing CM risk ( Figure   1 ).
In logistic regression models to identify predictors of obstructive CAD across the entire population (Figure 2) , CM risk factors and T2DM exhibited a strong and significant association with obstructive CAD. Typical angina was also associated with obstructive disease (OR = 1.6, p = 0.03). A stepwise increase in association with obstructive CAD was seen with low HDL (OR=0.98 for each 1 mg/dL increase, p<0.001), dysglycemia (OR=1.34 for each 1% (11 mmol/mol) increase in HbA1c, p<0.001), hypertriglyceridemia(OR=1.55, p=0.004), and hypertension (OR=3.50, p<0.001). The OR for obesity was not significant (OR=1.14, p=0.3).
Diabetes was a significant univariable predictor of obstructive CAD (OR=2.34 for patients with T2DM not requiring insulin and OR=4.79 for T2DM requiring insulin, p<0.001 for both). In the absence of diabetes, the presence of ≥ 3 CM risk factors was not associated with a numeric increase in the odds of obstructive CAD (univariable OR=1.21, p=0.4) but was associated with increased SIS and SSS (Figure 1 ).
Propensity Score for Insulin Use
Significant baseline characteristics associated with insulin use among patients with diabetes included age, male gender, low HDL cholesterol, hypertriglyceridemia, hypertension, higher BMI, and years diagnosed with T2DM. In the final propensity model for insulin use, the c-statistic was 0.91, p<0.001.
Cardiovascular Outcomes Across Cardiometabolic Risk
As Similar results were found when we assessed annualized risk of all-cause mortality (Supplemental figure 2).
When each CM risk group was stratified by severity of CAD, we found that increased stenosis by CCTA was associated with increased MACE (Figure 3 top panel) , although differences in cardiovascular death and MI (Figure 3, bottom panel) and all-cause mortality (Supplemental figure 2) were less pronounced.
To evaluate whether early revascularizations (occurring < 90 days post CCTA) influenced prognosis, we compared revascularization rates by metabolic group. Those with T2DM requiring insulin had a significantly increased rate of early revascularization (16% p < 0.001) but other groups did not differ significantly from one another (p= 0.3): 5.0% for those When restricted to patients with T2DM, those not requiring insulin and without stenosis by CCTA had the greatest long-term event-free survival while patients requiring insulin had an unfavorable prognosis that was further worsened in the presence of stenosis by CCTA (Figure 4, 
top panel).
In patients without T2DM, the poorest survival occurred in patients with both ≥3 CM risk factors and significant stenosis (Figure 4, bottom panel) . Notably, patients with significant stenosis and lower CM risk (<3 CM risk factors) had similar outcomes as patients with ≥3 CM risk factors and no stenosis (p=0.3).
To further examine the association between CM risk, CAD severity and prognosis, we constructed several univariable and multivariable Cox regression models for combined MACE (Supplemental Figure 3) . In univariable Cox models, diabetes, extent of CAD, presence of high-risk anatomy, and smoking were associated with risk of combined MACE and cardiac death or MI. In addition, the presence of diabetes was also strongly associated with combined MACE (HR=2.55, p<0.001) and cardiac death or MI (HR=2.89, p=0.004). A significant interaction (pinteraction = 0.008) occurred for diabetes and insulin use.
The final propensity weighted multivariable Cox regression model adjusted for age, smoking, propensity score for insulin use, and high-risk anatomy. In this model, age, current smoking, increasing CM risk category, and high risk CCTA were independently associated with adverse events (Supplemental Figure 3) . Analysis according to number of CM risks demonstrated that among those with T2DM, the presence of three additional CM risks was A finding of high risk CAD by CCTA significantly increased the propensity weighted multivariable hazard ratios for MACE in each group with increased CM risk (Supplemental Figure 4) . Similar trends were obtained from the univariate and multivariable models for CV death and MI in addition to all-cause mortality (data not shown).
Discussion
Our study demonstrates that that across categories of increasing cardiometabolic risk, there is a graded, dose-dependent association with the presence, extent, and severity of CAD as well as adverse cardiovascular prognosis. A particularly important finding is that among patients without T2DM, the presence of multiple CM risk factors is increasingly associated with risk of future cardiovascular events. Furthermore, among patients without T2DM, CM risk appears to modify the association between obstructive CAD and adverse prognosis, such that the presence of obstructive CAD most strongly impacts patients with higher CM risk. (Figure 3) Finally, among patients with T2DM (already at "high CM risk"), insulin use identifies a subgroup with a worse prognosis. Collectively, these results suggest CM risk is strongly associated with both CAD and cardiac events, and may be an important risk factor in CAD pathogenesis and prognosis before the onset of frank T2DM.
Our findings that patients with T2DM requiring insulin have a greater risk of events has also been shown by Berman et al. (40) who showed that individuals with T2DM requiring insulin Page 14 of 40 Diabetes Care have higher cardiac mortality, particularly if they also have an abnormal adenosine myocardial perfusion imaging study, when the annual cardiac mortality was 9%. However, our study had a lower event rate in this group (3% annual rate of cardiovascular death or MI), reflecting the lower risk associated with patients that undergo CCTA versus MPI. Moreover, while our study excluded all patients with prior CAD, nearly half of the patients with diabetes in the study by Berman et al underwent prior coronary revascularization. (40) The mechanism underlying the higher event rate of patients with T2DM requiring insulin is not known. Some have hypothesized that direct harmful effects of insulin therapy on endothelial dysfunction (41) (9) Recently, Wong et al also demonstrated that T2DM and the metabolic syndrome are associated with a higher rate of CAC progression and adverse cardiovascular outcomes (45) . Extending these observations, it has also been shown that the absence of CAC identifies patients at low risk:
Malik et al showed that even among patients with T2DM or the metabolic syndrome, the absence of CAC was associated with a favorable prognosis (3); similar findings have also been found by Raggi et al. (46) Our findings extend the results of these prior studies utilizing CAC. While these prior studies have focused on coronary calcifications in predominantly asymptomatic populations, our study is among the first to investigate the association of CM risk across patients with T2DM and patients without T2DM with CCTA, a more sensitive test for coronary plaque, which also can assess for coronary stenosis. Recent important studies by Rana(14) and Hadamitzky (15) demonstrated that CCTA has prognostic utility among patients with T2DM, although these studies utilized an endpoint of all-cause mortality and were unable to evaluate glycemic status or distinguish differences according to insulin use. Our analysis specifically evaluated the endpoint of cardiovascular mortality and non-fatal MI. Importantly, these prior studies and our analysis demonstrate that CCTA identities a subgroup of patients (those with no CAD) with an excellent prognosis in spite of guideline recommendations for consideration as being "high risk" by virtue of a diagnosis of T2DM. However since the proportion of patients with T2DM requiring insulin that have normal studies (i.e. no plaque and no stenosis) was only 20%, the yield of testing in this group may be low (i.e. number needed to scan to identify 1 normal study is 5).
Finally we show that HbA1c has utility not only to define glucose intolerance and diabetes as CM risk factors, but as a predictor of increasing severity of CAD. Specifically, we found a 34% increase in odds of obstructive CAD per 1% (11 mmol/mol) increase in HbA1C (Figure 2) . Interestingly, however, increasing HbA1C was not associated with worse prognosis.
This finding is in keeping with prior randomized trials which showed aggressive control of hyperglycemia among patients with T2DM reduced microvascular complications such as retinopathy but was not associated with benefit in cardiovascular outcomes, perhaps due to offtarget effects of insulin therapies. (47) Specifically, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial(48), the cardiovascular mortality rate of the intensive glucose lowering group (0.8% per year) was not significantly different from the standard therapy controls (0.6% per year). Notably, these event rates were comparable to the overall CV mortality rate in our study (0.8% per year among all those with T2DM). However, our finding is exploratory, as HbA1C assessment was cross-sectional and its association with risk may be influenced by disease-specific therapy.
The results of our study must be viewed in context with its design. Our study was retrospective, thus limiting full ascertainment of some risk factors for all patients who underwent CCTA. Thus, our sample size was reduced in order to include only patients with completely available data for all risk factors. Additionally, we did not use measures of central adiposity such as waist:hip ratio but rather used BMI. BMI is highly correlated(23) with and has similar predictive value for future onset of diabetes (24) or clinical CV disease(25) as waist-hip ratio.
Also, we did not obtain follow-up creatinine in order to assess for contrast nephropathy, as the rate of this complication is exceedingly low in clinical practice. For instance, among patients with T2DM referred for CT angiography for pulmonary embolus (a study which requires a higher dose of contrast than coronary CT; 120 mL versus 70 mL), there was no clinical case of renal failure although 4% of patients experienced an increase in creatinine of unknown clinical significance.(49) Because contrast nephropathy after CCTA is a rare event even among patients 
Conclusion
In conclusion, our study shows that CCTA identifies patients across a spectrum of baseline CM risk factors with differential CAD prevalence and prognosis at 3.1 years follow-up.
Patients without T2DM with increased CM risk have a similar prognosis as patients with T2DM
but not requiring insulin. On the other hand, among patients with T2DM, the need for insulin (7) 27 (4) 34 (7) 31 (7) 34 (8) <0.001 HbA1c, % 6.1(1) 5.6(0.3) 5.7(0.3) 6.5(1.1) 7.9(1.6) <0.001 Table 1 . Baseline demographics according to cardiometabolic risk. BMI = body mass index (kg/m 2 ); CM = cardiometabolic; DM = diabetes mellitus; HbA1c = hemoglobin A1c; HDL = high density lipoprotein; T2DM = type 2 diabetes mellitus.
